Additional agents, such as the BET inhibitor (JQI) and src inhibitor (Dasatinib), have also demonstrated promising preclinical efficacy in gastric cancer (Zhou et al., 2020; Wang et al., 2022). This evidence concerns the gene SRC and gastric cancer.